A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)
Latest Information Update: 12 Jan 2025
Price :
$35 *
At a glance
- Drugs Osimertinib (Primary) ; Savolitinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms SAFFRON
- Sponsors AstraZeneca; AstraZeneca AB
- 03 Jun 2024 Planned End Date changed from 30 Nov 2026 to 17 Dec 2026.
- 03 Jun 2024 Planned primary completion date changed from 30 May 2025 to 26 Jun 2025.
- 18 May 2023 Planned End Date changed from 3 Dec 2026 to 30 Nov 2026.